Momat Rhino Advance, 140 mcg+50 mcg/dose 150 doses spray

A combined anti-allergic agent (H1-histamine receptor blocker + GCS for topical use).

Indications

Nasal congestion, Sneezing, Allergic rhinitis, Allergies, Runny nose (rhinitis)

Rinitis

Active ingredient

Azelastine, Mometazone

Composition

Nasal spray

Active ingredients:

azelastine hydrochloride – 140 µg,

mometasone furoate – 50 µg.

Auxiliary substances:

Microcrystalline cellulose (Avicel RC-591) – 0.910 mg,

sodium carmellose -0.021 mg,

dextrose – 3.500 mg,

polysorbate-80 – 0.0175 mg,

benzalkonium chloride – 0.014 mg,

dinatrium edetate – 0.035 mg,

neotame – 0.0007 mg,

citric acid monohydrate – 0.0105 mg,

sodium citrate – 0.021 mg,

purified water – up to 70 mg.

How to take, the dosage

Intranasally.

The suspension contained in the bottle is inhaled using a special dispensing nozzle on the bottle.

1 dose of the spray (azelastine hydrochloride – 140 mcg/momstasone furoate – 50 mcg) into each nostril 2 times a day in the morning and in the evening.

The course of treatment is 2 weeks.

Interaction

Aselastin. There have been no clinically significant interactions with other medicinal products when using azelastip inhaled.

Mometasone furoate.Combination therapy with loratadine was well tolerated by patients.

There was no effect of the drug on plasma concentrations of loratadine or its major metabolite. In these studies, mometasone furoate was not detected in plasma (with a sensitivity of 50 pg/ml detection method).

.

Special Instructions

As with any long-term treatment, patients who have been using Momat Rhino Advance nasal spray for months or longer should periodically be monitored by a physician for possible nasal mucosal changes, nasal septal perforation (very rare) and possible systemic side effects.

If a local fungal infection of the nose or pharynx develops, it may be necessary to discontinue treatment with Momat Rhino Advance Nasal Spray and perform specific therapy. If persistent nasopharyngeal irritation develops, discontinuation of therapy should be considered.

Patients who switch to treatment with Momat Rhino Advans nasal spray after long-term therapy with systemic glucocorticosteroids require special attention. Withdrawal of systemic glucocorticosteroids in these patients may lead to insufficient adrenal function, which may take up to several months to recover. If signs of adrenal insufficiency occur, systemic glucocorticosteroids should be restarted and other necessary measures taken.

. During the transition from systemic glucocorticosteroid treatment to treatment with Momat Rhino Advance Nasal Spray, some patients may experience initial symptoms of withdrawal from systemic glucocorticosteroids (e.g. joint and/or muscle pain, fatigue and depression), despite a reduction in symptoms associated with nasal mucosal damage; These patients should be specifically encouraged to continue treatment with Momat Rhino Advance Nasal Spray.

The switch from systemic to topical glucocorticosteroids may also reveal pre-existing allergic conditions such as allergic conjunctivitis and eczema that were masked by systemic glucocorticosteroid therapy.

When intranasal steroids are used in doses higher than recommended or in sensitive patients at recommended doses, systemic glucocorticosteroid effects and adrenal suppression may develop. If these changes occur, the use of Momat Rhino Advance Nasal Spray should be gradually discontinued according to the procedures adopted for discontinuation of oral glucocorticosteroids.

Patients treated with glucocorticosteroids have potentially compromised immune reactivity and should be advised of their increased risk of infection if exposed to certain infectious diseases (e.g., chickenpox, measles) and the need for medical consultation if such contact occurs.

If there are signs of a significant bacterial infection (e.g., fever, persistent and severe pain on one side of the face or toothache, swelling of the orbital or periorbital area), immediate medical consultation is needed. Glucocorticosteroids for nasal and inhaled use can cause glaucoma and/or cataracts. Therefore, close monitoring of patients with changes in vision as well as patients who have a history of elevated intraocular pressure, glaucoma and/or cataracts should be performed.

Effect on the ability to drive vehicles and engage in other activities
In rare cases, fatigue, fatigue, dizziness and weakness, which may be a consequence of the disease itself, may develop when using Momat Rhino Advance Nasal Spray. In such cases, you should avoid driving a vehicle and working with complex machinery.

.

Contraindications

Hypersensitivity to the components of the drug

Side effects

Often: headache, dysgeusia (unpleasant taste) as a consequence of improper use, namely, if the head is tilted back excessively during insertion.

Very rarely: dizziness (may be caused by the disease itself).

Gastrointestinal tract disorders:
Rarely: sensation of irritation of the mucous membrane of the throat, nausea.

Respiratory system disorders, chest and mediastinal organs:

Often: nasal bleeding, nasal discomfort (burning sensation, itching), nasal mucous membrane ulceration, sneezing, pharyngitis, sinusitis, upper respiratory tract infections.

Immune system disorders:

Very rarely: hypersensitivity, anaphylactoid reactions.

Skin and subcutaneous tissue disorders:

Very rarely: rash, skin itching, urticaria.

General disorder and disorders at the site of administration:

Very rare: fatigue, drowsiness, weakness (may be caused by the disease itself).

With long-term use of glucocorticosteroids (GCS) in high doses, systemic side effects may develop, including glaucoma and cataracts.

Overdose

There are currently no known cases of overdose when administered by ingestion. In case of azelastine overdose due to accidental ingestion, nervous system disorders (drowsiness, confusion, tachycardia, hypotension) may occur. The therapy of these disorders is symptomatic in nature.

Long-term use of glucocorticosteroids in high doses, as well as simultaneous use of several GCS may suppress hypothalamic-pituitary-adrenal system.

In view of low systemic bioavailability of the drug, it is unlikely that in case of accidental or intentional overdose any measures other than observation will be required with possible subsequent resumption of the drug in recommended dose.